百利天恒BL-B01D1更新进展

药智网2025-07-08

近日，百利天恒自主研发的全球首创双抗ADC药物BL-B01D1在治疗局部晚期或转移性鼻咽癌的III期临床试验中取得了重大进展。分析结果显示，该药物已成功达到主要终点，或将为鼻咽癌患者带来新的治疗选择。鼻咽癌是一种具有高度侵袭性和复发倾向的头颈部恶性肿瘤，尽管近年来免疫治疗和靶向治疗取得了一定进展，但对于复发性或转移性鼻咽癌患者，尤其是经过多线治疗失败的患者，治疗选择仍然有限。百利天恒的BL-...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2549964455?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-08 11:24","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2549964455","market":"sh","top_or_hot":-1,"title":"百利天恒BL-B01D1更新进展","media":"药智网","content":"<div>\n<p>近日，百利天恒自主研发的全球首创双抗ADC药物BL-B01D1在治疗局部晚期或转移性鼻咽癌的III期临床试验中取得了重大进展。分析结果显示，该药物已成功达到主要终点，或将为鼻咽癌患者带来新的治疗选择。鼻咽癌是一种具有高度侵袭性和复发倾向的头颈部恶性肿瘤，尽管近年来免疫治疗和靶向治疗取得了一定进展，但对于复发性或转移性鼻咽癌患者，尤其是经过多线治疗失败的患者，治疗选择仍然有限。百利天恒的BL-...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708112626a69c3114&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>百利天恒BL-B01D1更新进展</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n百利天恒BL-B01D1更新进展\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-08 11:24 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708112626a69c3114&s=b><strong>药智网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>近日，百利天恒自主研发的全球首创双抗ADC药物BL-B01D1在治疗局部晚期或转移性鼻咽癌的III期临床试验中取得了重大进展。分析结果显示，该药物已成功达到主要终点，或将为鼻咽癌患者带来新的治疗选择。鼻咽癌是一种具有高度侵袭性和复发倾向的头颈部恶性肿瘤，尽管近年来免疫治疗和靶向治疗取得了一定进展，但对于复发性或转移性鼻咽癌患者，尤其是经过多线治疗失败的患者，治疗选择仍然有限。百利天恒的BL-...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708112626a69c3114&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708112626a69c3114&s=b","article_id":"2549964455","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708112626a69c3114&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2549964455","pubTimestamp":1751945052,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"近日，百利天恒自主研发的全球首创双抗ADC药物BL-B01D1在治疗局部晚期或转移性鼻咽癌的III期临床试验中取得了重大进展。百利天恒的BL-B01D1正是在这一背景下应运而生，它以其独特的创新药物机制，为鼻咽癌治疗带来了新的思路。分析结果显示，BL-B01D1在这些关键指标上均达到了预期目标，显示出显著的疗效和良好的安全性。值得一提的是，BL-B01D1的国际化进程也在稳步推进。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688506":"百利天恒","BK0239":"医药制造"},"translate_title":"Baili Tianheng BL-B01D1 update progress","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688506":1},"content_text":"近日，百利天恒自主研发的全球首创双抗ADC药物BL-B01D1在治疗局部晚期或转移性鼻咽癌的III期临床试验中取得了重大进展。分析结果显示，该药物已成功达到主要终点，或将为鼻咽癌患者带来新的治疗选择。鼻咽癌是一种具有高度侵袭性和复发倾向的头颈部恶性肿瘤，尽管近年来免疫治疗和靶向治疗取得了一定进展，但对于复发性或转移性鼻咽癌患者，尤其是经过多线治疗失败的患者，治疗选择仍然有限。百利天恒的BL-B01D1正是在这一背景下应运而生，它以其独特的创新药物机制，为鼻咽癌治疗带来了新的思路。BL-B01D1是一种EGFR×HER3双抗ADC药物，其设计原理是通过同时靶向表皮生长因子受体（EGFR）和人表皮生长因子受体3（HER3）两个关键靶点，阻断肿瘤细胞的信号传导通路，从而抑制肿瘤的生长和转移。这种双靶点设计不仅提高了药物的精准性，还增强了其抗肿瘤活性。在之前的I期临床试验中，BL-B01D1已经展现出令人瞩目的疗效：在37例可评估疗效的鼻咽癌患者中，客观缓解率（ORR）达到59.5%。这些数据为III期临床试验的成功奠定了坚实的基础。图1 BL-B01D1药品概览图片来源：药智数据此次III期临床试验（研究方案编号：BL-B01D1-303）的顺利推进，进一步验证了BL-B01D1在鼻咽癌后线治疗中的潜力。试验的主要终点为客观缓解率（ORR）和总生存期（OS），次要终点包括缓解持续时间（DoR）和无进展生存期（PFS）。分析结果显示，BL-B01D1在这些关键指标上均达到了预期目标，显示出显著的疗效和良好的安全性。值得一提的是，BL-B01D1的国际化进程也在稳步推进。2023年12月，百利天恒与全球龙头药企百时美施贵宝（BMS）签订了潜在总交易额达84亿美元的独家许可与合作协议。这一合作不仅为BL-B01D1的全球研发和商业化提供了强大的支持，也标志着中国创新药在全球市场的影响力不断提升。目前，BL-B01D1还在中国和美国开展40余项针对多种肿瘤类型的临床试验，未来有望在更多适应症中取得突破。参考来源：1.药智数据2.https://finance.sina.com.cn/roll/2025-07-03/doc-infecyit3710732.shtml声明：本内容仅用作医药行业信息传播，不代表药智网立场。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2549964455","isCrawlerRequest":true}